Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047697 · ClinicalTrials.gov registry record · Phase 2
Donepezil HCl & Cognitive Deficits in Autism
A Phase 2 study of Autistic Disorder, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT00047697 is a Phase 2 study of Autistic Disorder that has completed, run by University of Pittsburgh. The registered enrollment target is 34 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00047697, a Phase 2 study of Autistic Disorder, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donepezil HCl
Study Locations (1)
Pennsylvania
- Western Psychiatric Institute & Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047697
The ClinicalTrials.gov registry entry for NCT00047697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (70% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00047697 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00047697 about?
NCT00047697 is a clinical study titled "Donepezil HCl & Cognitive Deficits in Autism". This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.
What is the current status of trial NCT00047697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2002-10. Estimated completion is 2006-08.
What conditions does trial NCT00047697 study?
This clinical trial studies the following conditions: Autistic Disorder.
What interventions are being tested in trial NCT00047697?
The interventions under investigation include: Placebo (DRUG), Donepezil HCl (DRUG).
Who is sponsoring clinical trial NCT00047697?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047697 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
COMPLETED · Phase 2
-
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.